Takeda Pharmaceutical Co Stock In The News

TAK Stock  USD 15.01  0.02  0.13%   
Our overall analysis of Takeda Pharmaceutical's news coverage and content from conventional and social sources shows investors' bearish mood towards Takeda Pharmaceutical Co. The specific impact of Takeda Pharmaceutical news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Takeda Pharmaceutical's overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Takeda Pharmaceutical headlines in addition to utilizing other, more conventional financial analysis modules. Check out Takeda Pharmaceutical Backtesting and Takeda Pharmaceutical Hype Analysis.

Takeda Pharmaceutical Today Top News and Investor Outlook

Yahoo News
TAK or DSNKY: Which Is the Better Value Stock Right Now?
https://finance.yahoo.com/news/tak-dsnky-better-value-stock-154008572.html
 Bullish
Yahoo News
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer
https://finance.yahoo.com/news/takeda-protagonist-therapeutics-partnered-investigational-170141358.html
 Neutral
Investors Business Daily at Macroaxis
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
https://finance.yahoo.com/news/value-investors-buy-takeda-pharmaceutical-144019451.html
 Bullish
Yahoo News
Protagonist, Takeda Say Phase 3 Study of Rusfertide Meets Endpoints in Polycythemia Vera
https://finance.yahoo.com/news/protagonist-takeda-phase-3-study-140038900.html
 Neutral
Yahoo News
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
https://finance.yahoo.com/news/protagonist-takeda-announce-positive-topline-114500048.html
 Neutral
Yahoo News
Is Takeda Pharmaceutical Company Limited (TAK) the Best Low Price Pharma Stock to Invest In Right Now?
https://finance.yahoo.com/news/takeda-pharmaceutical-company-limited-tak-134320152.html
 Bullish
Yahoo News
The European Medicines Agency (EMA) Has ...
https://finance.yahoo.com/news/european-medicines-agency-ema-approved-080100583.html
 Bullish
Yahoo News
TAK vs. DSNKY: Which Stock Is the Better Value Option?
https://finance.yahoo.com/news/tak-vs-dsnky-stock-better-164013572.html
 Bullish
Yahoo News
Is Takeda Pharmaceutical Company Limited (TAK) the Best Japanese Stock to Buy in 2025?
https://finance.yahoo.com/news/takeda-pharmaceutical-company-limited-tak-194332882.html
 Neutral
Investors Business Daily at Macroaxis
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
https://finance.yahoo.com/news/investors-undervaluing-takeda-pharmaceutical-co-144015484.html
 Bullish

Takeda Pharmaceutical Co Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Takeda and other traded companies coverage with news coverage. We help investors stay connected with Takeda headlines for the 15th of March 2025 to make an informed investment decision based on correlating the impacts of news items on Takeda Stock performance. Please note that trading solely based on the Takeda Pharmaceutical Co hype is not for everyone as timely availability and quick action are needed to avoid losses.
Takeda Pharmaceutical's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Takeda Pharmaceutical Co investors visualize upcoming and past events in order to time the market based on Takeda Pharmaceutical Co noise-free hype analysis.
Takeda Pharmaceutical stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Takeda earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Takeda Pharmaceutical that are available to investors today. That information is available publicly through Takeda media outlets and privately through word of mouth or via Takeda internal channels. However, regardless of the origin, that massive amount of Takeda data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Takeda Pharmaceutical news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Takeda Pharmaceutical relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Takeda Pharmaceutical's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Takeda Pharmaceutical alpha.

Takeda Largest EPS Surprises

Earnings surprises can significantly impact Takeda Pharmaceutical's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-05-09
2024-03-31-0.0142-0.00650.007754 
2023-05-22
2023-03-310.05050.0740.023546 
2022-10-27
2022-09-300.17570.1345-0.041223 
2018-10-31
2018-09-300.230.27360.043618 
2018-05-14
2018-03-31-0.37-0.31420.055815 
2021-02-04
2020-12-310.45360.3968-0.056812 
View All Earnings Estimates

Takeda Pharmaceutical Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Takeda Pharmaceutical Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
Yahoo News
14th of March 2025
TAK or DSNKY Which Is the Better Value Stock Right Now
at finance.yahoo.com 
news
11th of March 2025
Investors Research Corp Cuts Stake in Takeda Pharmaceutical Company Limited
at thelincolnianonline.com 
Yahoo News
5th of March 2025
XPOVIO Continues to Disrupt the Oncology Market with Expanded Indications and Strong Marke...
at finance.yahoo.com 
Macroaxis News: globenewswire.com
4th of March 2025
2025 Anti-CD38 Antibody Pipeline Insights for 10 Companies and 12 Pipeline Drugs, Includin...
at globenewswire.com 
Gurufocus Stories at Macroaxis
3rd of March 2025
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of ...
at gurufocus.com 
Simply Wall St News at Macroaxis
27th of February 2025
Earnings Tell The Story For Takeda Pharmaceutical Company Limited
at simplywall.st 
Yahoo News
26th of February 2025
Takeda broadens its deal with BridGene for up to 770m
at finance.yahoo.com 
Yahoo News
18th of February 2025
Mucopolysaccharidosis Market Analysis Across 7MM Unveiling Growth Opportunities Across Dif...
at finance.yahoo.com 
Simply Wall St News at Macroaxis
4th of February 2025
Takeda Pharmaceutical Company Limited Earnings Missed Analyst Estimates Heres What Analyst...
at simplywall.st 
seekingalpha News
30th of January 2025
Takeda Pharmaceutical Non-GAAP EPS of 443.00, revenue of 3528.2B raises FY outlook
at seekingalpha.com 

Takeda Pharmaceutical Investors Sentiment

The influence of Takeda Pharmaceutical's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Takeda. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Takeda Pharmaceutical's public news can be used to forecast risks associated with an investment in Takeda. The trend in average sentiment can be used to explain how an investor holding Takeda can time the market purely based on public headlines and social activities around Takeda Pharmaceutical Co. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Takeda Pharmaceutical's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Takeda Pharmaceutical's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Takeda Pharmaceutical's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Takeda Pharmaceutical.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Takeda Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Takeda Pharmaceutical's short interest history, or implied volatility extrapolated from Takeda Pharmaceutical options trading.
When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:
Check out Takeda Pharmaceutical Backtesting and Takeda Pharmaceutical Hype Analysis.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.78)
Dividend Share
192
Earnings Share
0.44
Revenue Per Share
1.5 K
Quarterly Revenue Growth
0.03
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.